Gilead Sciences Inc【GILD】株式ニュース | ADVFN

US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Gilead Sciences Inc (GILD)
Gilead Sciences Inc (GILD) ニュース

Gilead Sciences Inc (GILD)

116.04

0.60

(0.52%)

終了 3月7日 6:00AM

115.90

-0.14

(-0.12%)

取引時間後: 9:55AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 144 - Report of proposed sale of securities

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

– One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

– Now Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area...

Form 4 - Statement of changes in beneficial ownership of securities

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual...

Form 144 - Report of proposed sale of securities

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

– If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV Prevention Choice – – FDA to Review Applications Under Priority Review...

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Form 144 - Report of proposed sale of securities

Greedy G

Greedy G 3週前

~sold the 2/14 $108 calls @.20c

Greedy G

Greedy G 3週前

~bought the 2/14 $108 calls @.05c ahead of earnings today

fink

Looks like the National Sales meeting in Vegas, has employees dumping after this high.
Management must not be painting much hope for the future.

I can't wait to hear what the pump is to keep employees from bailing out.

jondoeuk

jondoeuk 3月前

They now add an investigational HIV vaccine to its portfolio https://www.fiercebiotech.com/biotech/gilead-buys-hiv-vaccine-spanish-biotech-following-success-clinical-collab

Data on the vaccine in combination with vesatolimod https://www.ddw-online.com/hiv-combination-regimen-could-lead-to-viral-remission-22215-202302/

jondoeuk

jondoeuk 3月前

Based on recent data*, I would have thought that getting KITE-509 into the clinic (for GPC3+ solid tumours, not just 3L+ HCC) would be a priority.

* https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019 https://www.nature.com/articles/s41586-024-08261-8

fink

CEO is talking now.
The stock is selling off on great words.
Go figure! 6month Prep shot is a game changer. Generics are already being made for third world nations. These guys are going to eradicate AIDS.

They should be allowed to make a buck or two.
I want $250 a share please, I've held it way too long.

Monksdream

Monksdream 4月前

Monksdream

Monksdream 4月前

GILD a new 52 week high

Monksdream

Monksdream 4月前

GILD new 52=week high

jondoeuk

jondoeuk 5月前

Two years later, and here are some of my takeaways...

- They know they need to expand into more (rural) areas and that might include pre-built clean rooms. Slides 21-26 show how difficult it is to drive uptake further. "Majority of future growth expected from establishing new ATC's in community." These centres need to establish new relationships with others for apheresis, local ER's for (CRS/ICANS) emergencies and even local freezer storage requirements, which is it's own thing. So much goes into treatment that has nothing to do with manufacturing.

- Forgot ZUMA-12 data was that good. A 86% CR rate and 81% three-year survival from 1L patients. Not sure how to compare that to later line trials, but decades from now, let's hope we are at the point we treat this front line (vs SOC now). Kite said their COGS is

jondoeuk

jondoeuk 5月前

''There have been more than 250 HIV vaccine trials, most of them early-stage, looking at whether the vaccine is safe and whether we mount an immune response following vaccination. There have been very few vaccine trials—10 or so—that have advanced to the point of looking at efficacy. Of those, one showed 31% efficacy at 42 months. That was the most promising trial, but the efficacy fell off very quickly, and it was only 31% and only against clade B. Whether that would translate to the other clades is not clear.'' https://publichealth.jhu.edu/2022/why-dont-we-have-an-hiv-vaccine

jondoeuk

jondoeuk 5月前

https://x.com/JackSha90859576/status/1847728103021281381

TechandBio

TechandBio 5月前

Wants to go higher!

$GILD

Monksdream

Monksdream 6月前

GILD approaching a 52 week high

north40000

north40000 6月前

Featured on CNBC-TV this morning, 8:40 a.m. time frame.

TechandBio

TechandBio 7月前

NICE!

clutch stock with a disruptive cure prevention vaccine for HIV people would rather take 2 shots a year not to get HIV then taking oral pills for treatment!

$GILD

TechandBio

TechandBio 7月前

Adding shares and calls under $80..00

HIV Cure Vaccine is a big deal data is incredible flawless. Oncology pipeline is building nicely.

$GILD
$GILD

midastouch017

midastouch017 7月前

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

https://finance.yahoo.com/news/compugen-announces-fda-clearance-ind-110000034.html

FDA clearance triggers a $30 million milestone payment from Gilead

Monksdream

Monksdream 7月前

GILD under $100

TechandBio

TechandBio 7月前

Target is $100-$120 by Q2 2025

$GILD

TechandBio

TechandBio 7月前

HIV Prevention CURE Shot 2x a year

Great growing oncology pipeline!

my $80 vertical Calls from last week are looking golden!

$GILD

north40000

north40000 9月前

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602784

"Gilead plans to share new preclinical data for an oral GLP-1 at the upcoming American Diabetes Association conference starting June 21… The asset, dubbed GS-4571, has previously demonstrated 5% to 8% weight loss in monkeys in 28 to 30 days…"

north40000

north40000 9月前

How about oral GLP-1 news? CNBC-TV AH today. Portal Innovations CEO interview.

jondoeuk

jondoeuk 9月前

There is barely any move on this news. Seems the market had already written it off. O'Day needs to go, they need to rebuild in areas they have expertise in and refocus in oncology.

jondoeuk

jondoeuk 9月前

A double whammy https://www.oncologypipeline.com/apexonco/asco-2024-full-evoke-01-result-adds-gileads-trodelvy-problems

jondoeuk

jondoeuk 9月前

They guided that a third of revenues will be from oncology by 2030...! https://www.businesswire.com/news/home/20240530516266/en/Gilead-Provides-Update-on-Phase-3-TROPiCS-04-Study

jondoeuk

jondoeuk 9月前

''Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors.'' https://www.nature.com/articles/s43018-024-00768-3

https://medicalxpress.com/news/2024-05-cancer-optimal-cells.html

jondoeuk

jondoeuk 9月前

The oNKo-Innate team, along with scientists at Kite, have just published a research article https://onlinelibrary.wiley.com/doi/10.1002/cti2.1507

Optimised manufacturing dramatically improves lentiviral transduction efficiency of primary human NK cells. The field has progressed greatly with CAR transduction rates in human NK cells (it was ~5% just a few years ago). The oNKo-Innate R&D team were able to raise CAR transduction efficiency to ~80%. After testing various NK cell sources, they conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make PB-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

''No doubt CAR-NK cells have faced several challenges in oncology settings, and we hope our new findings assist researchers in addressing some of these challenges while also improving the potential for CAR-NK cell therapies in treating autoimmune disease such as lupus'' said Nicholas Huntington, PhD, oNKo-innate's CSO.

jondoeuk

jondoeuk 10月前

The management has been substandard for many years https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels and https://www.fiercepharma.com/pharma/gilead-writes-24b-trodelvy-ceo-underscores-time-focused-execution

jondoeuk

jondoeuk 11月前

IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve

jondoeuk

jondoeuk 11月前

Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.

jondoeuk

jondoeuk 12月前

Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf

jondoeuk

jondoeuk 12月前

I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and

jondoeuk

jondoeuk 12月前

Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568

Monksdream

Monksdream 1年前

GILD new 52 week high

jondoeuk

jondoeuk 1年前

Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.

jondoeuk

jondoeuk 1年前

Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

There have been a number of these over the years, but nothing seems to come of them

jondoeuk

jondoeuk 1年前

The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.

Greedy G

Greedy G 1年前

~bought 9/22 $80 calls .08c

jondoeuk

jondoeuk 2年前

Q1 results https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171789595

DewDiligence

DewDiligence 2年前

Why is an oral prodrug of Remdesivir anything to get excited about?

jondoeuk

jondoeuk 2年前

Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-details-promising-early-covid-223448308.html

jondoeuk

jondoeuk 2年前

Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma

What's big is that the trial reached five year maturity instead of just the number of deaths. Looking at it, more than 210 of the 359 (58%) are still alive at five years compared to 43% in ZUMA-1 (3L+). Sure, these were healthier patients, but the CR rate was more double (65% vs. 32%) against the standard of care. So, treatment works better in healthier patients. ZUMA-23 in 1L (against R-CHOP) is ongoing.

The next question is whether treating healthier patients with multiple myeloma (if they can resolve supply issues with auto) can (significantly) improve PFS.

fink

Christmas sell off over, last day to lock in any paper tax loss. LOL

Who’s losing money here?

I think we start the trend back up into Q1

fink

It wants $90.
I got a sell order in @88, but think it will continue up.
Gilead is moving away from HIV and more into this cancer thingy.

That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too

Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price

PennyPusher786

PennyPusher786 2年前

It's at a 3 year high

fung_derf

fung_derf 2年前

Very funny that you posted this to me. I couldn't recall, but knew there were a couple of you who followed me over here. It has had a pretty nice month.

I_luv_cydy

Re: fung_derf post# 3875

Tuesday, May 19, 2020 2:32:23 PM

Post#
3878
of 4839
Fung: Why do you suppose GILD keeps dropping? I'm a shareholder for a while.

fink

Nice to see GILD over $80

Wonder if I should trim some? It’s been eating chit pie for some time.
Still don’t see why the spike.

jondoeuk

jondoeuk 2年前

Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers https://www.businesswire.com/news/home/20221020005633/en/Kite-and-Refuge-Biotechnologies-Announce-Exclusive-License-Agreement-for-Investigational-Gene-Expression-Platform-for-Blood-Cancers

Some preclinical data from Refuge Bio https://jitc.bmj.com/content/8/Suppl_3/A86.2 https://jitc.bmj.com/content/9/Suppl_2/A162 https://jitc.bmj.com/content/9/Suppl_2/A164 https://jitc.bmj.com/content/8/Suppl_3/A458.2

Zeppo

Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.

Gilead Sciences

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約